Protara Therapeutics
Protara Therapeutics is dedicated to advancing transformative therapies for people with cancer and rare diseases. The company values creativity, diverse perspectives, and tenacity to bring life-changing therapies to patients. They focus on reflecting the diverse world we live in to better understand and treat cancer and rare diseases, often without boundaries of age, gender, race, religion, or socioeconomic background. Protara applies modern scientific, regulatory, and manufacturing advancements to create new, accelerated development opportunities.
Industries
Nr. of Employees
small (1-50)
Protara Therapeutics
Products
TARA-002
An investigational cell-based therapeutic derived from a characterized master cell bank; being developed for non-muscle invasive bladder cancer and lymphatic malformations with local administration approaches (intravesical or intracystic).
IV Choline Chloride
An investigational intravenous phospholipid substrate replacement therapy intended to prevent or treat choline deficiency and associated liver dysfunction in patients receiving parenteral support.
TARA-002
An investigational cell-based therapeutic derived from a characterized master cell bank; being developed for non-muscle invasive bladder cancer and lymphatic malformations with local administration approaches (intravesical or intracystic).
IV Choline Chloride
An investigational intravenous phospholipid substrate replacement therapy intended to prevent or treat choline deficiency and associated liver dysfunction in patients receiving parenteral support.
Services
Clinical development and trial execution
Design, operational execution, and management of clinical studies across adult and pediatric populations, including Phase 2 open-label and registrational trial formats.
Expanded access (compassionate use) evaluation
Assessment and consideration of individual patient requests to access investigational therapies outside clinical trials, following defined eligibility criteria and regulatory requirements.
Clinical development and trial execution
Design, operational execution, and management of clinical studies across adult and pediatric populations, including Phase 2 open-label and registrational trial formats.
Expanded access (compassionate use) evaluation
Assessment and consideration of individual patient requests to access investigational therapies outside clinical trials, following defined eligibility criteria and regulatory requirements.
Expertise Areas
- Clinical trial management
- Cell therapy development
- Formulation development for intravenous therapies
- Regulatory strategy and designation management
Key Technologies
- Cell therapy (master cell bank–derived products)
- Intravesical instillation delivery
- Intracystic injection delivery
- Intravenous phospholipid substrate replacement formulation